AP2655A - Capsule formulation of pirfenidone and pharmaceutically acceptable excipients - Google Patents

Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Info

Publication number: AP2655A
Authority: AP; ARIPO
Prior art keywords: pirfenidone; pharmaceutically acceptable; acceptable excipients; capsule formulation; capsule
Prior art date: 2005-09-22

Application number

AP2008004390A

Other languages

English (en)

Other versions

AP2008004390A0 (en

Inventor

Ramachandran Radhakrishnan

Ronald Vladyka

Kenneth Sultzbaugh

Original Assignee

Intermune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-22

Filing date

2006-09-22

Publication date

2013-05-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-22 Application filed by Intermune Inc filed Critical Intermune Inc

2008-04-30 Publication of AP2008004390A0 publication Critical patent/AP2008004390A0/xx

2013-05-07 Application granted granted Critical

2013-05-07 Publication of AP2655A publication Critical patent/AP2655A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AP2008004390A 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients AP2655A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72025705P	2005-09-22	2005-09-22
PCT/US2006/037057 WO2007038315A2 (en)	2005-09-22	2006-09-22	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Publications (2)

Publication Number	Publication Date
AP2008004390A0 AP2008004390A0 (en)	2008-04-30
AP2655A true AP2655A (en)	2013-05-07

Family

ID=37898745

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AP2008004390A AP2655A (en)	2005-09-22	2006-09-22	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
AP2012006231A AP2012006231A0 (en)	2005-09-22	2006-09-22	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AP2012006231A AP2012006231A0 (en)	2005-09-22	2006-09-22	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.

Country Status (28)

Country	Link
US (5)	US7988994B2 (es)
EP (2)	EP1940364B2 (es)
JP (3)	JP5837732B2 (es)
KR (3)	KR101675651B1 (es)
CN (3)	CN101267810A (es)
AP (2)	AP2655A (es)
AU (2)	AU2006295440B2 (es)
BR (1)	BRPI0616324A2 (es)
CA (2)	CA2620380C (es)
CU (1)	CU20080043A7 (es)
CY (1)	CY1115544T1 (es)
DK (1)	DK1940364T4 (es)
EA (1)	EA030093B1 (es)
EC (1)	ECSP088394A (es)
ES (1)	ES2496144T5 (es)
GE (1)	GEP20115303B (es)
IL (2)	IL189273A (es)
MA (1)	MA29875B1 (es)
MX (1)	MX2008003882A (es)
NO (1)	NO345131B1 (es)
NZ (3)	NZ591443A (es)
PL (1)	PL1940364T5 (es)
PT (1)	PT1940364E (es)
SI (1)	SI1940364T2 (es)
TN (1)	TNSN08136A1 (es)
UA (2)	UA115861C2 (es)
WO (1)	WO2007038315A2 (es)
ZA (1)	ZA200802237B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100777169B1 (ko)	2001-01-29	2007-11-16	시오노기세이야쿠가부시키가이샤	5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
CA2608116A1 (en)	2005-05-10	2006-11-16	Intermune, Inc.	Method of modulating stress-activated protein kinase system
NZ591443A (en) †	2005-09-22	2013-04-26	Intermune Inc	Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP2471534A1 (en)	2006-12-18	2012-07-04	Intermune, Inc.	Method of providing pirfenidone therapy to a patient
US20080242293A1 (en) *	2007-04-02	2008-10-02	Cequint, Inc.	System and method for providing caller id name display in wireless communications system
WO2008147169A2 (es) *	2007-05-29	2008-12-04	Cell Therapy Technology, S.A. De C.V.	Microemolsion conteniendo pirfenidona
JP5587184B2 (ja)	2007-06-20	2014-09-10	オースペックス・ファーマシューティカルズ・インコーポレイテッド	繊維症阻害剤としての置換ｎ−アリールピリジノン
MX2007009796A (es)	2007-08-14	2009-02-25	Cell Therapy And Technology S	Gel conteniendo pirfenidona.
US8093210B2 (en) *	2008-03-07	2012-01-10	Solanan, Inc.	Treatment of sepsis with 5-ethyl-1-phenyl-2(1H)-pyridone
CA3034994A1 (en)	2008-06-03	2009-12-10	Intermune, Inc.	Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US7635707B1 (en)	2008-11-10	2009-12-22	Intermune, Inc.	Pirfenidone treatment for patients with atypical liver function
AP2011005824A0 (en) *	2009-01-26	2011-08-31	Intermune Inc	Methods for treating acute myocardial infarctions and associated disorders.
EP3255146B1 (en)	2009-03-16	2019-05-15	Pangu Biopharma Limited	Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
US7816383B1 (en)	2009-12-04	2010-10-19	Intermune, Inc.	Methods of administering pirfenidone therapy
CN101912395B (zh) *	2010-08-12	2012-09-26	北京凯因科技股份有限公司	一种含吡非尼酮的药物组合物及其制备方法
US10105356B2 (en)	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2824432C (en)	2011-01-31	2021-10-19	Genoa Pharmaceuticals, Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012225611B2 (en)	2011-03-08	2016-09-15	Auspex Pharmaceuticals, Inc.	Substituted N-Aryl pyridinones
CN102670632A (zh) *	2011-03-12	2012-09-19	赵海静	吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es)	2011-07-19	2012-07-11	Cell Therapy And Technology S A De C V	Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013090439A1 (en) *	2011-12-12	2013-06-20	Orbis Biosciences, Inc.	Sustained release particle formulations of guaifenesin
MX346763B (es)	2012-03-28	2017-03-31	Cell Therapy And Tech S A De C V	Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es)	2012-08-23	2018-06-04	Grupo Medifarma S A De C V Star	Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) *	2012-08-31	2016-03-22	Intermune, Inc.	Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
JP6397479B2 (ja)	2013-03-15	2018-09-26	エータイアーファーマ，インコーポレイテッド	ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
HK1220133A1 (zh)	2013-03-15	2017-04-28	Intermune, Inc.	改善微血管完整性的方法
ES2745983T3 (es) *	2013-12-13	2020-03-04	Novartis Ag	Formas de dosificación farmacéutica
NZ722927A (en)	2014-01-10	2022-07-29	Avalyn Pharma Inc	Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2943363A1 (en)	2014-04-02	2015-10-08	Intermune, Inc.	Anti-fibrotic pyridinones
CN106456697B (zh) *	2014-04-11	2019-12-17	珍白斯凯尔有限公司	具有纤维化抑制活性的肽和含有其的组合物
US20170224667A1 (en) *	2014-10-15	2017-08-10	Arata AZUMA	Cancer chemopreventive agent
CA2937365C (en) *	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) *	2016-07-12	2021-11-11	日商鹽野義製藥股份有限公司	吸入用醫藥組成物
KR102051559B1 (ko) *	2016-12-09	2019-12-05	재단법인 아산사회복지재단	섬유증의 진단 또는 치료를 위한 스테아르산의 용도
KR20180100869A (ko) *	2017-03-02	2018-09-12	영진약품 주식회사	피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
CN110536694A (zh) *	2017-04-20	2019-12-03	Atyr 医药公司	用于治疗肺部炎症的组合物和方法
MX366086B (es)	2017-08-15	2019-06-27	Cell Therapy And Tech S A De C V	Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
PT3511001T (pt) *	2018-01-12	2021-12-29	Tiefenbacher Alfred E Gmbh & Co Kg	Formulação de comprimido e cápsula contendo pirfenidona
US20210205253A1 (en) *	2018-05-31	2021-07-08	The Asan Foundation	Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
US20210267955A1 (en) *	2018-06-29	2021-09-02	Zenvision Pharma Llp	Low dose oral pharmaceutical composition of pirfenidone or salt thereof
WO2020115774A1 (en)	2018-12-06	2020-06-11	Cipla Limited	High drug load extended release formulations
BR112022010891A2 (pt)	2019-12-04	2022-08-16	Idorsia Pharmaceuticals Ltd	Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
EP4122471A4 (en) *	2020-02-06	2025-02-19	Ribomic Inc	THERAPEUTIC AGENT FOR SUBRETINAL HYPERREFLECTIVE MATERIAL OR RETINAL DISORDERS ASSOCIATED WITH SUBRETINAL HYPERREFLECTIVE MATERIAL
WO2021181368A1 (en) *	2020-03-13	2021-09-16	Puretech Lyt 100, Inc.	Methods of treating respiratory disease with deupirfenidone
EP4125890A1 (en)	2020-04-01	2023-02-08	Boehringer Ingelheim International GmbH	Use of biomarkers in the treatment of fibrotic conditions
BR112022020821A2 (pt) *	2020-04-14	2022-12-20	Excalibur Pharmaceuticals Inc	Pirfenidona para tratamento de coronavírus
WO2021215856A1 (ko) *	2020-04-22	2021-10-28	영진약품 주식회사	안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법
EP4541368A3 (en)	2021-01-25	2025-07-02	Nibec Co., Ltd.	Peptide for preventing and treating fibrosis
CN117224429B (zh) *	2023-11-15	2024-02-06	南京天纵易康生物科技股份有限公司	一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1049411A (en) *	1972-12-18	1979-02-27	Affiliated Medical Research	N-substituted pyridone and general method for preparing pyridones
US4052509A (en)	1972-12-18	1977-10-04	Affiliated Medical Research, Inc.	Method for reducing serum uric acid levels
US4042699A (en)	1972-12-18	1977-08-16	Affiliated Medical Research, Inc.	Method for reducing serum glucose levels
JPH02215719A (ja)	1989-02-15	1990-08-28	Yamauchi Akitomo	線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) *	1989-11-22	1998-02-10	Margolin; Solomon B.	Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) *	1989-11-22	1996-05-21	Margolin; Solomon B.	Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) *	1989-11-22	1994-05-10	Margolin Solomon B	Composition and method for reparation and prevention of fibrotic lesions
ATE224712T1 (de) *	1993-05-07	2002-10-15	Solomon B Margolin	Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
US5591766A (en) *	1993-12-03	1997-01-07	Cheil Foods & Chemicals, Inc.	Solid oral formulations of pyridone carboxylic acids
US6090822A (en) *	1995-03-03	2000-07-18	Margolin; Solomon B.	Treatment of cytokine growth factor caused disorders
US5962478A (en) *	1995-09-19	1999-10-05	Margolin; Solomon B.	Inhibition of tumor necrosis factor α
DE69637050T2 (de) *	1995-09-19	2008-06-19	Margolin, Solomon B., Dallas	Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
US20030104066A1 (en) *	2000-03-27	2003-06-05	Kouji Murai	Easy-to-take granules
KR100777169B1 (ko) *	2001-01-29	2007-11-16	시오노기세이야쿠가부시키가이샤	5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
WO2002087549A1 (fr) *	2001-04-25	2002-11-07	Taisho Pharmaceutical Co., Ltd.	Comprimes a liberation prolongee du type a unites multiples
US7007089B2 (en) *	2001-06-06	2006-02-28	Akarnai Technologies, Inc.	Content delivery network map generation using passive measurement data
US7512702B1 (en) *	2002-03-19	2009-03-31	Cisco Technology, Inc.	Method and apparatus providing highly scalable server load balancing
US7139840B1 (en) *	2002-06-14	2006-11-21	Cisco Technology, Inc.	Methods and apparatus for providing multiple server address translation
CA2496314A1 (en)	2002-08-27	2004-03-11	Intermune, Inc.	Methods of treating idiopathic pulmonary fibrosis
WO2004019863A2 (en) *	2002-08-28	2004-03-11	Intermune, Inc.	Combination therapy for treatment of fibrotic disorders
US7159034B1 (en) *	2003-03-03	2007-01-02	Novell, Inc.	System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards
US20060063832A1 (en) *	2003-03-31	2006-03-23	Pliva-Lachema A.S. A Czech Republic Corporation	Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
US20070092488A1 (en)	2003-05-16	2007-04-26	Intermune Inc.	Methods of treating idiopathic pulmonary fibrosis
CN101039957A (zh)	2003-05-16	2007-09-19	因特缪恩公司	合成的趋化因子受体配体及其使用方法
MXPA06000178A (es) *	2003-07-01	2006-04-11	Pharmacia & Upjohn Co Llc	Solidos modulados en la fase de difusion.
US7407973B2 (en)	2003-10-24	2008-08-05	Intermune, Inc.	Use of pirfenidone in therapeutic regimens
JP4614884B2 (ja)	2003-11-14	2011-01-19	シャンハイゲノミックスインク	ピリドンの誘導体とその使用
SE0400235D0 (sv) *	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
US8642079B2 (en) *	2004-02-23	2014-02-04	Hormos Medical Corporation	Solid formulations of ospemifene
US7584435B2 (en) *	2004-03-03	2009-09-01	Omniture, Inc.	Web usage overlays for third-party web plug-in content
KR101294467B1 (ko) *	2005-07-25	2013-09-09	인터뮨, 인크.	Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
NZ591443A (en) *	2005-09-22	2013-04-26	Intermune Inc	Granule formation of pirfenidone and pharmaceutically acceptable excipients

2005
- 2005-09-22 NZ NZ591443A patent/NZ591443A/xx unknown
2006
- 2006-09-22 SI SI200631819T patent/SI1940364T2/sl unknown
- 2006-09-22 MX MX2008003882A patent/MX2008003882A/es active IP Right Grant
- 2006-09-22 AP AP2008004390A patent/AP2655A/xx active
- 2006-09-22 ES ES06815221T patent/ES2496144T5/es active Active
- 2006-09-22 NZ NZ600129A patent/NZ600129A/en unknown
- 2006-09-22 UA UAA201203869A patent/UA115861C2/uk unknown
- 2006-09-22 JP JP2008532431A patent/JP5837732B2/ja active Active
- 2006-09-22 WO PCT/US2006/037057 patent/WO2007038315A2/en not_active Ceased
- 2006-09-22 BR BRPI0616324-6A patent/BRPI0616324A2/pt not_active Application Discontinuation
- 2006-09-22 KR KR1020147004496A patent/KR101675651B1/ko active Active
- 2006-09-22 KR KR1020137022095A patent/KR101645069B1/ko active Active
- 2006-09-22 CA CA2620380A patent/CA2620380C/en active Active
- 2006-09-22 EA EA200800881A patent/EA030093B1/ru active Protection Beyond IP Right Term
- 2006-09-22 NZ NZ565957A patent/NZ565957A/en unknown
- 2006-09-22 PT PT68152214T patent/PT1940364E/pt unknown
- 2006-09-22 UA UAA200805048A patent/UA99433C2/ru unknown
- 2006-09-22 US US12/067,712 patent/US7988994B2/en active Active
- 2006-09-22 CN CNA2006800348742A patent/CN101267810A/zh active Pending
- 2006-09-22 AU AU2006295440A patent/AU2006295440B2/en not_active Revoked
- 2006-09-22 GE GEAP200610558A patent/GEP20115303B/en unknown
- 2006-09-22 CN CN2013103433683A patent/CN103393607A/zh active Pending
- 2006-09-22 CA CA2762013A patent/CA2762013C/en active Active
- 2006-09-22 CN CN201410057564.9A patent/CN103735530A/zh active Pending
- 2006-09-22 PL PL06815221.4T patent/PL1940364T5/pl unknown
- 2006-09-22 CU CU20080043A patent/CU20080043A7/es unknown
- 2006-09-22 KR KR1020087006806A patent/KR20080046673A/ko not_active Ceased
- 2006-09-22 EP EP06815221.4A patent/EP1940364B2/en active Active
- 2006-09-22 AP AP2012006231A patent/AP2012006231A0/xx unknown
- 2006-09-22 EP EP11007850A patent/EP2431025A1/en not_active Withdrawn
- 2006-09-22 DK DK06815221.4T patent/DK1940364T4/da active
- 2006-09-22 ZA ZA200802237A patent/ZA200802237B/xx unknown
2008
- 2008-02-04 IL IL189273A patent/IL189273A/en active IP Right Grant
- 2008-02-12 NO NO20080759A patent/NO345131B1/no unknown
- 2008-03-19 TN TNP2008000136A patent/TNSN08136A1/en unknown
- 2008-04-17 MA MA30855A patent/MA29875B1/fr unknown
- 2008-04-22 EC EC2008008394A patent/ECSP088394A/es unknown
2009
- 2009-04-17 US US12/426,182 patent/US7767225B2/en active Active
2011
- 2011-04-05 AU AU2011201520A patent/AU2011201520B2/en not_active Revoked
- 2011-06-16 US US13/162,048 patent/US8383150B2/en active Active
2012
- 2012-08-17 JP JP2012180913A patent/JP5715101B2/ja active Active
2013
- 2013-02-25 US US13/776,079 patent/US8753679B2/en active Active
2014
- 2014-05-07 US US14/271,720 patent/US20140242159A1/en not_active Abandoned
- 2014-06-24 JP JP2014129551A patent/JP2014169341A/ja active Pending
- 2014-09-10 CY CY20141100731T patent/CY1115544T1/el unknown
2015
- 2015-07-09 IL IL239868A patent/IL239868A0/en unknown

Also Published As

Publication number	Publication date
SI1940364T2 (sl)	2022-11-30
BRPI0616324A2 (pt)	2011-06-14
CN101267810A (zh)	2008-09-17
NZ600129A (en)	2013-12-20
PT1940364E (pt)	2014-09-04
JP2009509962A (ja)	2009-03-12
US20090191265A1 (en)	2009-07-30
JP2012224641A (ja)	2012-11-15
ZA200802237B (en)	2010-04-28
EP1940364B2 (en)	2022-07-20
DK1940364T3 (da)	2014-06-30
UA115861C2 (uk)	2018-01-10
KR101675651B1 (ko)	2016-11-11
AU2006295440B2 (en)	2011-01-06
IL189273A (en)	2016-09-29
HK1117762A1 (en)	2009-01-23
IL189273A0 (en)	2008-06-05
KR101645069B1 (ko)	2016-08-02
US20100152250A1 (en)	2010-06-17
CN103393607A (zh)	2013-11-20
US7988994B2 (en)	2011-08-02
SI1940364T1 (sl)	2014-09-30
CA2762013C (en)	2014-07-08
US20130165484A1 (en)	2013-06-27
PL1940364T5 (pl)	2023-02-27
UA99433C2 (ru)	2012-08-27
NZ565957A (en)	2012-04-27
JP5837732B2 (ja)	2015-12-24
CY1115544T1 (el)	2017-01-04
US7767225B2 (en)	2010-08-03
US8753679B2 (en)	2014-06-17
NZ591443A (en)	2013-04-26
EA200800881A1 (ru)	2008-08-29
MX2008003882A (es)	2009-02-27
AP2008004390A0 (en)	2008-04-30
TNSN08136A1 (en)	2009-07-14
ECSP088394A (es)	2008-05-30
EP2431025A1 (en)	2012-03-21
AU2011201520A1 (en)	2011-04-28
CA2762013A1 (en)	2007-04-05
NO345131B1 (no)	2020-10-12
DK1940364T4 (da)	2022-10-24
CA2620380C (en)	2012-10-30
AP2012006231A0 (en)	2012-04-30
MA29875B1 (fr)	2008-10-03
EA030093B1 (ru)	2018-06-29
KR20130100381A (ko)	2013-09-10
CN103735530A (zh)	2014-04-23
IL239868A0 (en)	2015-08-31
JP2014169341A (ja)	2014-09-18
ES2496144T3 (es)	2014-09-18
EP1940364B1 (en)	2014-06-11
JP5715101B2 (ja)	2015-05-07
US20140242159A1 (en)	2014-08-28
AU2006295440A1 (en)	2007-04-05
PL1940364T3 (pl)	2014-11-28
CU20080043A7 (es)	2011-04-26
NO20080759L (no)	2008-06-18
ES2496144T5 (es)	2022-11-21
US20120015984A1 (en)	2012-01-19
EP1940364A2 (en)	2008-07-09
AU2011201520B2 (en)	2013-04-11
GEP20115303B (en)	2011-10-10
CA2620380A1 (en)	2007-04-05
KR20080046673A (ko)	2008-05-27
WO2007038315A2 (en)	2007-04-05
KR20140029554A (ko)	2014-03-10
US8383150B2 (en)	2013-02-26
WO2007038315A3 (en)	2007-07-12

Publication	Publication Date	Title
AP2655A (en)	2013-05-07	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
IL184735A0 (en)	2007-12-03	Pharmaceutical formulations and methods of use
AP2008004447A0 (en)	2008-04-30	Orally absorbed pharmaceutical formulation and method of administration
TWI367212B (en)	2012-07-01	Dosage forms of palonosetron hydrochloride having improved stability and bioavailability
ZA200901110B (en)	2009-12-30	Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same
IL196854A (en)	2013-07-31	Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
IL188744A0 (en)	2008-12-29	High drug load formulations and dosage forms
IL202111A0 (en)	2010-06-16	Formulations for the oral administration of therapeutic agents and related methods
IL184697A0 (en)	2007-12-03	Injectable preparations of diclofenic and its pharmaceutically acceptable salts
IL178067A0 (en)	2006-12-31	Pharmaceutical dosage forms and compositions
PL1655026T3 (pl)	2010-01-29	Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
EP1968609A4 (en)	2010-06-09	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS
PL385455A1 (pl)	2008-11-24	Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
IL191922A0 (en)	2009-08-03	Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP1855647A4 (en)	2010-11-17	DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MANUFACTURING THE SAME
EP1740541A4 (en)	2009-07-22	THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
GB0711654D0 (en)	2007-07-25	Formulations for production of capsule shells and capsules
WO2007119249A3 (en)	2008-05-22	Pharmaceutical compositions of cefixime
GB0610207D0 (en)	2006-07-05	New forms of active pharmaceutical ingredient
PL380757A1 (pl)	2008-04-14	Nowe pochodne epirubicyny, ich nowe zastosowanie medyczne oraz farmaceutycznie akceptowalna postać leku
HK1123205A (en)	2009-06-12	Orally absorbed pharmaceutical formulation and method of administration